On ECHEMI
Home > Drugs > Nanjing Pharmaceutical FACTORY Co., Ltd.
Nanjing Pharmaceutical FACTORY Co., Ltd.
  • Founded in:

    1991-07-11
  • Country:

    China China
  • Address:

    No. 26, Xingang Avenue, Nanjing Economic and Technological Development Zone
  • Tax NO.:

    91320192134908655F
  • Registered Funds:

    200.8 million yuan
  • Website:

  • Email:

Related Drugs
Sucralfate
Name Description Content CAS NO. Registered Holders
Sucralfate

Extract from the above information

More

Extract from the above information

54182-58-0 22
Sertrolast Tablets
±-ζ-(2,4,5-trimethyl-3,6-dicarbonyl-1,4-cyclohexadien-1-yl)phenylheptanoic acid
Name Description Content CAS NO. Registered Holders
±-ζ-(2,4,5-trimethyl-3,6-dicarbonyl-1,4-cyclohexadien-1-yl)phenylheptanoic acid

This product is a thromboxane A2 receptor antagonist, which can inhibit the vasoconstriction reaction caused by various chemical transmitters (thromboxane A2, leukotriene D4, platelet activating factor), inhibit the immediate and delayed allergic reactions induced by antigen inhalation, and improve lung function.

More

This product is a thromboxane A2 receptor antagonist, which can inhibit the vasoconstriction reaction caused by various chemical transmitters (thromboxane A2, leukotriene D4, platelet activating factor), inhibit the immediate and delayed allergic reactions induced by antigen inhalation, and improve lung function.

0
Oxaliplatin for injection
The main ingredient of this product is oxaliplatin. Its chemical name is: (1R-trans)-(1,2-cyclohexanediamine-N,N)[oxalate (Z-)-O,O]platinum.
Name Description Content CAS NO. Registered Holders
Oxaliplatin

It is a new platinum derivative. The central platinum atom is surrounded by oxalic acid and 1,2-diaminocyclohexane, presenting a trans conformation, and is a stereoisomer. It acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA rapidly, taking up to 15 minutes. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin.

More

It is a new platinum derivative. The central platinum atom is surrounded by oxalic acid and 1,2-diaminocyclohexane, presenting a trans conformation, and is a stereoisomer. It acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA rapidly, taking up to 15 minutes. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin.

61825-94-3 56
Sucralfate Capsules
Name Description Content CAS NO. Registered Holders
Sucralfate

This product can form a thin film on the surface of damaged gastric mucosa, thereby resisting the invasion of gastric acid on the mucosa and protecting the gastric mucosa. In addition, sucralfate can absorb pepsin and neutralize gastric acid, but the effect is weak.

More

This product can form a thin film on the surface of damaged gastric mucosa, thereby resisting the invasion of gastric acid on the mucosa and protecting the gastric mucosa. In addition, sucralfate can absorb pepsin and neutralize gastric acid, but the effect is weak.

54182-58-0 22
Clodronate Disodium Tablets
Clodronate disodium.
Name Description Content CAS NO. Registered Holders
Clodronate disodium Salt

This product is a bone metabolism regulator that can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts.

More

This product is a bone metabolism regulator that can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts.

22560-50-5 0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.